XOMA Corporation (XOMA) |
|
27.22 2.21 (8.84%)
|
02-14 16:00 |
|
Open: |
25.17 |
Pre. Close: |
25.01 |
|
High:
|
27.32 |
Low:
|
25.08 |
|
Volume:
|
52,021 |
Market Cap:
|
266M |
|
|
|
|
XOMA Corp is a biotechnology company. It discovers and develops human and humanized monoclonal antibody-based therapeutics. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
27.345 - 27.478 |
27.478 - 27.592 |
|
Low:
|
24.782 - 24.926 |
24.926 - 25.05 |
|
Close:
|
26.989 - 27.228 |
27.228 - 27.434 |
|
Technical analysis |
as of: 2020-02-14 4:33:55 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 31.91 One year: 37.27 |
| Support: |
Support1: 24.16 Support2: 22.20 |
| Resistance: |
Resistance1: 27.32 Resistance2: 31.91 |
| Pivot: |
24.44 |
| Moving Average: |
MA(5): 25.47 MA(20): 24.33
MA(100): 22.95 MA(250): 18.78 |
| MACD: |
MACD(12,26): 0.25 Signal(9): -0.06 |
| Stochastic oscillator: |
%K(14,3): 84.90 %D(3): 79.46 |
| RSI: |
RSI(14): 66.25 |
| 52-week: |
High: 28.85 Low: 11.58 Change(%): 91.6 |
| Average Vol(K): |
3-Month: 7687 10-Days: 5529 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.XOMA has closed above the upper band by 10.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 6.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
2019-11-20
The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov.
2019-11-19
The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) Crispr Therapeutics AG (NASDAQ: CRSP ) DexCom, Inc. (NASDAQ: DXCM Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) )(announced a partnership with Novo Nordisk A/S (NYSE: NVO ) for developing RNAi therapies) Frequency Therapeutics Inc (NASDAQ: FREQ )(reacted to its third-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Karuna Therapeutics Inc (NASDAQ: KRTX )( announced positive results for its mid-stage schizophrenia drug) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO )(announced full results of its ORION-9 Phase 3 study of inclisiran at the American Heart Association 2019 annual meeting) Medtronic PLC (NYSE: MDT ) Neurocrine Biosciences, Inc.
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
